Table 4 Determinants for clinical worsening and overall survival

From: Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

 

Clinical worsening

Overall survival

Univariable analysis

Multivariable analysis

 

Univariable analysis

Multivariable analysis

 

No. out of 178 (%)

nevents/npatients

HR (95% CI)

P value (Wald)

HR (95% CI)

P value (Wald)

nevents/npatients

HR (95% CI)

P value (Wald)

HR (95% CI)

P value (Wald)

Gender

   

0.19

    

0.17

  

Female

102 (57%)

23/102

1

   

14/102

1

   

Male

76 (43%)

24/76

1.47 (0.83–2.61)

   

17/76

1.64 (0.81–3.32)

   

Age at diagnosis

   

0.50

    

0.04

  

<70 years

128 (72%)

32/128

1

   

18/128

1

   

≥70 years

50 (28%)

15/50

1.24 (0.67–2.28)

   

13/50

2.13 (1.04–4.36)

   

BMI

   

0.39

    

0.52

  

<18.5

12 (7%)

5/12

1.63 (0.60–4.43)

   

4/12

2.34 (0.73–7.45)

   

18.5–25

64 (39%)

17/64

1

   

10/64

1

   

25–30

62 (38%)

12/62

0.76 (0.36–1.60)

   

9/62

1.05 (0.43–2.59)

   

≥30

25 (15%)

8/25

1.43 (0.61–3.33)

   

4/25

1.16 (0.36–3.69)

   

Smoking (n = 152 with informative data)

   

0.03

    

0.01

  

Never

89 (59%)

17/89

1

   

10/89

1

   

Current/former

63 (41%)

22/63

2.03 (1.07–3.82)

   

17/63

2.78 (1.27–6.08)

   

ECOG at last follow-up

   

<0.0001

 

<0.0001

  

<0.0001

 

<0.0001

0–1

129 (73%)

22/129

1

 

1

 

9/129

1

 

1

 

≥2

48 (27%)

25/48

3.61 (2.03–6.42)

 

3.25 (1.81–5.85)

 

22/48

7.49 (3.45–16.3)

 

5.83 (2.60–13.1)

 

Type of cancer

   

0.09

 

0.33

  

0.45

  

Solid tumor

150 (84%)

36/150

1

 

1

 

27/150

1

   

Hematological malignancy

28 (16%)

11/28

1.80 (0.91–3.55)

 

1.42 (0.70–2.88)

 

4/28

0.67 (0.23–1.90)

   

Onco-hematological status

   

0.13

    

0.007

 

0.15

Remission/ localized

70 (39%)

13/70

1

   

4/70

1

 

1

 

Active/metastatic

108 (61%)

34/108

1.64 (0.86–3.11)

   

27/108

4.23 (1.48–12.1)

 

2.22 (0.75–6.58)

 

Treatment in the past 3 months

   

0.20

    

0.17

  

No

58 (33%)

11/58

1

   

6/58

1

   

Yes

117 (67%)

35/117

1.55 (0.79–3.06)

   

24/117

1.87 (0.77–4.59)

   

Cytotoxic chemotherapy in the past 3 months

   

0.008

 

0.09

  

0.03

 

0.23

No

112 (63%)

21/112

1

 

1

 

13/112

1

 

1

 

Yes

66 (37%)

26/66

2.18 (1.22–3.87)

 

1.69 (0.92–3.10)

 

18/66

2.20 (1.08–4.49)

 

1.56 (0.76–3.20)

 

Targeted therapy in the past 3 months

   

0.66

    

0.09

  

No

148 (83%)

40/148

1

   

29/148

1

   

Yes

30 (17%)

7/30

0.83 (0.37–1.86)

   

2/30

0.29 (0.07–1.24)

   

Immune checkpoint inhibitors in the past 3 months

   

0.39

    

0.94

  

No

159 (89%)

44/159

1

   

28/159

1

   

Yes

19 (11%)

3/19

0.60 (0.19–1.93)

   

3/19

1.05 (0.32–3.45)

   

Hormone therapy in the past 3 months (patient with a solid tumor only)

   

0.85

    

0.89

  

No

140 (90%)

33/140

1

   

24/140

1

   

Yes

16 (10%)

4/16

1.11 (0.39–3.13)

   

3/16

1.09 (0.33–3.61)

   
  1. The hazard ratio corresponds to the effect size of the covariable studied on the risk of clinical worsening or death. Statistical significance was determined by Cox models using the Wald test. Due to the exploratory nature of the analyses, no formal adjustment for multiplicity was done. All tests were two sided and significance was accepted at the 5% level.
Back to article page